TOBAM’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.49M | Buy |
2,394
+1,791
| +297% | +$1.22M | 0.36% | 77 |
|
|
2026
Q1 | $466K | Buy |
603
+105
| +21% | +$80.4K | 0.12% | 147 |
|
|
2025
Q4 | $384K | Buy |
+498
| New | +$338K | 0.09% | 157 |
|
|
2025
Q3 | – | Sell |
-2
| Closed | -$1K | – | 268 |
|
|
2025
Q2 | $1K | Hold |
2
| – | – | ﹤0.01% | 250 |
|
|
2025
Q1 | $1K | Sell |
2
-595
| -100% | -$409K | ﹤0.01% | 249 |
|
|
2024
Q4 | $425K | Sell |
597
-347
| -37% | -$291K | 0.13% | 110 |
|
|
2024
Q3 | $992K | Sell |
944
-114
| -11% | -$127K | 0.18% | 93 |
|
|
2024
Q2 | $1.11M | Sell |
1,058
-2,517
| -70% | -$2.44M | 0.17% | 86 |
|
|
2024
Q1 | $3.44M | Sell |
3,575
-989
| -22% | -$940K | 0.31% | 63 |
|
|
2023
Q4 | $4.01M | Sell |
4,564
-730
| -14% | -$601K | 0.35% | 53 |
|
|
2023
Q3 | $4.36M | Sell |
5,294
-2,274
| -30% | -$1.79M | 0.35% | 56 |
|
|
2023
Q2 | $5.44M | Sell |
7,568
-7,161
| -49% | -$5.52M | 0.41% | 59 |
|
|
2023
Q1 | $12.1M | Sell |
14,729
-5,577
| -27% | -$4.21M | 0.8% | 43 |
|
|
2022
Q4 | $14.7M | Buy |
20,306
+6,251
| +44% | +$4.61M | 0.97% | 39 |
|
|
2022
Q3 | $9.68M | Sell |
14,055
-3,959
| -22% | -$2.49M | 0.68% | 49 |
|
|
2022
Q2 | $10.6M | Sell |
18,014
-18,663
| -51% | -$12.1M | 0.67% | 50 |
|
|
2022
Q1 | $25.6M | Buy |
36,677
+1,481
| +4% | +$937K | 1.29% | 27 |
|
|
2021
Q4 | $22.2M | Sell |
35,196
-9,721
| -22% | -$5.98M | 1% | 39 |
|
|
2021
Q3 | $27.2M | Buy |
44,917
+2,499
| +6% | +$1.55M | 1.15% | 39 |
|
|
2021
Q2 | $23.7M | Sell |
42,418
-1,174
| -3% | -$595K | 0.95% | 43 |
|
|
2021
Q1 | $20.6M | Buy |
43,592
+249
| +0.6% | +$121K | 0.88% | 47 |
|
|
2020
Q4 | $20.9M | Buy |
43,343
+3,001
| +7% | +$1.62M | 0.93% | 39 |
|
|
2020
Q3 | $22.6M | Buy |
40,342
+14,174
| +54% | +$8.59M | 1.13% | 35 |
|
|
2020
Q2 | $16.3M | Buy |
26,168
+24,054
| +1,138% | +$13.7M | 1.05% | 38 |
|
|
2020
Q1 | $1.03M | Buy |
+2,114
| New | +$872K | 0.08% | 99 |
|
|
2018
Q4 | – | Sell |
-47,719
| Closed | -$19.3M | – | 166 |
|
|
2018
Q3 | $19.3M | Buy |
47,719
+7,716
| +19% | +$2.94M | 0.82% | 43 |
|
|
2018
Q2 | $13.8M | Buy |
40,003
+5,816
| +17% | +$1.82M | 0.57% | 57 |
|
|
2018
Q1 | $11.8M | Buy |
34,187
+29,095
| +571% | +$10.1M | 0.48% | 69 |
|
|
2017
Q4 | $1.91M | Buy |
+5,092
| New | +$2.06M | 0.08% | 118 |
|
|
2015
Q3 | – | Sell |
-4,760
| Closed | -$2.43M | – | 146 |
|
|
2015
Q2 | $2.43M | Sell |
4,760
-45
| -0.9% | -$22K | 0.09% | 112 |
|
|
2015
Q1 | $2.17M | Buy |
+4,805
| New | +$2.04M | 0.07% | 111 |
|
Other funds holding REGN
TOBAM's REGN Position: Q2 2026 in Review
TOBAM increased its Regeneron Pharmaceuticals (REGN) stake by 297% in Q2 2026, buying an estimated $1.22M and bringing the position to 2,394 shares worth $1.49M. The position accounts for 0.36% of the portfolio, ranked #77.
TOBAM first reported a position in REGN in Q1 2015 and has held it in 31 quarters since. The position peaked at $27.2M in Q3 2021. 1,334 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- TOBAM held 2,394 shares of Regeneron Pharmaceuticals worth $1.49M as of Q2 2026.
- TOBAM bought 1,791 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $1.22M.
- Regeneron Pharmaceuticals made up 0.36% of TOBAM's portfolio in Q2 2026, its #77 holding.
- TOBAM first reported a position in Regeneron Pharmaceuticals in Q1 2015 and has held it in 31 quarters since.
- TOBAM's Regeneron Pharmaceuticals position peaked at $27.2M in Q3 2021.
- 1,334 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on TOBAM's 13F filing for Q2 2026, filed 31 Jul 2026.